Buying from the EU? See Retatrutide for European research buyers.

Retatrutide is an investigational triple-receptor agonist that engages the GLP-1, GIP and glucagon receptors in a single molecule, studied in metabolic and body-composition research. Supplied lyophilised for laboratory research use only.
Retatrutide is a single-molecule triple-receptor agonist that simultaneously engages the GLP-1, GIP and glucagon receptors. It is among the most-discussed compounds in current metabolic research following large phase-2 clinical readouts.
By combining three incretin and energy-metabolism pathways in one peptide, research models examine effects on energy intake, energy expenditure and hepatic lipid handling that single- or dual-agonists do not fully reproduce.
| Area | Reported research focus |
|---|---|
| Weight regulation | Dose-dependent reductions in body weight in phase-2 cohorts. |
| Glycaemic control | Glucose-dependent insulin-secretion pathways. |
| Hepatic lipids | Glucagon-linked mobilisation of liver fat. |
| Specification | Detail |
|---|---|
| Product | Retatrutide |
| Format | Lyophilised vial |
| Fill | 10 mg per vial |
| Molecular formula | C221H342N46O68 |
| Purity | Specified to a 99%+ purity target — per-batch documentation will be published once independent lab testing completes |
| Price | €120.00 |
| Availability | In stock — dispatched from Ireland within 1–2 working days, tracked |
| Supplied for | Laboratory research use only — not for human consumption, diagnostic or therapeutic use |
Every production batch is sent for independent, third-party analysis at Janoshik Analytical. When results return, the full Certificate of Analysis for the exact batch you receive is published here and in our COA library, carrying its SHA-256 checksum and the lot number printed on your vial, so you can confirm the document is genuine and untampered. We publish every certificate, including any that fail.